Back to results
US 2023/0414755 A1Published application
Methods and compositions relating to genetically engineered cells expressing chimeric antigen receptors
AssigneeVor Biopharma Inc.
InventorsSadik Kassim, Julian Scherer, Giacomo Canesin, Tirtha Chakraborty
Life of this patent
Estimating the term…
Abstract
The disclosure is directed to methods and compositions relating to genetically engineered cells expressing chimeric antigen receptors, where the cells are mobilized lymphocytes.
Claims71
A genetically engineered cell, comprising
- a heterologous nucleic acid encoding a chimeric antigen receptor (CAR) targeting a lineage-specific cell-surface antigen associated with a hyperproliferative disease,
- wherein the cell is a mobilized lymphocyte cell, or a descendant thereof.
A method, comprising
- contacting a mobilized lymphocyte obtained from a first subject with a heterologous nucleic acid encoding a chimeric antigen receptor (CAR) targeting a lineage-specific cell-surface antigen associated with a hyperproliferative disease, thereby producing a genetically engineered lymphocyte expressing the CAR.
Dependencies are inferred from the claim text.